There is no contradiction. If a new trial were to ever get off the ground through slow dilution then Advent would benefit for sure. That’s what I meant. Otherwise, I don’t really care about Advent. I am fine with Advent making money as long as they don’t dilute and there is immediate ROI for NWBO shareholders.
That third party could be Oncovir. I have already said Oncovir partnership PR will be issued, but markets will simply dismiss it. No one would care. Big pharma will not allow NWBO to front run them in any announcements like they made in the last 10Q even if they didn’t provide any names. Big pharma is extremely careful around insider trading allegations, etc. So I am certain they were not referring to big pharma there and even if they were there would be no financial dealings as part of this arrangement and big pharma does not think of it as significant and PR worthy. NWBO likely exaggerated it in the last 10Q.
NWBO diluted 500M shares since data lock in addition to some of the loans they took. Let that sink in to understand how much cash they raised since data lock. So they will slow roll the combo trials over the next couple of years and keep bag holders on the hook! No reason why they can’t raise couple of hundred million dollars over the next 2-3 years after UK approval (in the same manner they did after data lock). They already have commitment for $50M from one group. Perhaps one or two more such groups might agree to purchase C shares after UK approval?
Either way, I expect a ton of dilution in 2025 and 2026.
Market Data 
Markets 
AI
